Chromadex is a Los Angeles-based bioscience company focused on developing proprietary ingredient technologies, including NAD+ research. It operates through Consumer Products, Ingredients, and Analytical Reference Standards segments, employing 106 staff since its IPO in 2007.
NAGE has been in the news recently: On June 26, multiple directors and board members of Niagen Bioscience exercised significant stock options, as disclosed in various SEC filings. The individuals involved included Steven Rubin, Jeong James Lee, Cohen, Wendy Tak Wing Yu, and another board member named Patrick.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
